| Project/Area Number |
21249069
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ITO Akihiko 東京大学, 医科学研究所, 講師 (90241984)
KANAMOTO Akira 東京大学, 医科学研究所, 助教 (10386021)
SATO Marimo 東京大学, 医科学研究所, 助教 (50401253)
地主 将久 北海道大学, 遺伝子病制御研究所, 准教授 (40318085)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
JIMUSHI Masahisa 北海道大学, 遺伝子病制御研究所, 准教授 (40318085)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥46,930,000 (Direct Cost: ¥36,100,000、Indirect Cost: ¥10,830,000)
Fiscal Year 2011: ¥15,080,000 (Direct Cost: ¥11,600,000、Indirect Cost: ¥3,480,000)
Fiscal Year 2010: ¥15,080,000 (Direct Cost: ¥11,600,000、Indirect Cost: ¥3,480,000)
Fiscal Year 2009: ¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
|
|---|
| Keywords | 実験外科学 / 腫瘍免疫 / 細胞療法 / 遺伝子治療 / 臨床研究 / ウイルスベクター / ウィルスベクター |
|---|
| Research Abstract |
In order to develop cellular-gene therapy against cancer, we have successfully produced cGMP-grade adeniviral vector expressing IL-12. We also performed preclinical safety examination for clinical trials using dendritic cells engineered to produce IL-12 at a high level. Furthermore, we have found the blockade of MFG-E8, an opsonin for phagocytosis, could enhance immune response against cancer cells as a basic research. These results, including generation of clinical grade vector, preclinical safety testing, and basic research to further enhance systemic immune responses, enables the development of novel approach to treat cancer.
|
